VYNE Therapeutics Reports 2025 Second Quarter Financial Results and Provides Business Update
Implemented cost reductions extend cash runway into first half of 2027BRIDGEWATER, N.J., Aug. 14, 2025 (GLOBE NEWSWIRE) -- VYNE Therapeutics...
Day: August 14, 2025
Chemomab Therapeutics Announces Second Quarter 2025 Financial Results and Provides Corporate Update
—Phase 3 Preparations Ongoing as Company Continues to Advance Multiple Partnering Options for Executing the Nebokitug Phase 3 Program— —Phase...
Lifeward Ltd. Reports Second Quarter 2025 Financial Results
Achieves record number of ReWalk systems placed for Medicare beneficiaries since fee schedule established Third consecutive quarter of U.S. ReWalk...
ZyVersa Therapeutics Highlights Data Demonstrating a Critical Need for Therapies to Address Kidney Lipotoxicity to Alleviate Diabetic Kidney Disease (DKD) and Its Progression
Data show that diabetes-associated metabolic issues lead to kidney lipid accumulation, resulting in inflammation and fibrosis that cause progressive kidney...
OneMedNet Reports 80% Reduction in Debt Enabling Focus On Growth
MINNEAPOLIS, Aug. 14, 2025 (GLOBE NEWSWIRE) -- OneMedNet Corporation (Nasdaq:ONMD) (“OneMedNet,” the “Company,” “we,” “us” or “our”), a leader in...
Avicanna Reports Q2 2025
TORONTO, Aug. 14, 2025 (GLOBE NEWSWIRE) -- Avicanna Inc. (“Avicanna” or “Company”) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN) a biopharmaceutical...
Evaxion announces business update and second quarter 2025 financial results
COPENHAGEN, Denmark, August 14, 2025 - Evaxion A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered...
Palvella Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update
Phase 3 SELVA trial evaluating QTORIN™ 3.9% rapamycin anhydrous gel (QTORIN™ rapamycin) for microcystic lymphatic malformations completed enrollment, exceeding enrollment...
Abeona Therapeutics® Reports Second Quarter 2025 Financial Results and Corporate Updates
- Received FDA approval for ZEVASKYN™ (prademagene zamikeracel), the first and only autologous cell-based gene therapy for the treatment of...
Cassava Reports Q2 2025 Financials Results and Provides Business Update
Following positive preclinical data, simufilam development to advance with a clinical study expected to begin in H1 2026 for the...
Cannara Biotech Enhances Financial Flexibility Through Strategic Asset Sale
MONTREAL, Aug. 14, 2025 (GLOBE NEWSWIRE) -- Cannara Biotech Inc. (“Cannara”, “the Company”, “us” or “we”) (TSXV: LOVE) (OTCQB: LOVFF)...
Lexeo Therapeutics Reports Second Quarter 2025 Financial Results and Operational Highlights
Breakthrough Therapy designation granted for LX2006 based on interim data from Phase I/II trials demonstrating clinically meaningful improvements in cardiac and...
NeuroOne® Reports Third Quarter Fiscal Year 2025 Financial Results; Revenue Increases 105% YoY and Gross Margin Expands to 53.9%
Completed Oversubscribed $8.2 Million Capital Raise; Funded Through At Least Fiscal Year 2026 EDEN PRAIRIE, Minn., Aug. 14, 2025 (GLOBE...
MiNK Therapeutics Reports Clinical and Strategic Milestones and Second Quarter 2025 Results
Cash runway extended to deliver clinical program in GVHD and Ph2 results in 2L Gastric CancerDepartment of Defense STTR Grant...
MediPharm Strengthens Global Position in Q2 2025, with 14% Revenue Growth and 50% Increase in International Medical Cannabis
Q2 Revenue of $11.8 Million, an Increase of 14% over Q2 202450% Growth in Revenue for International Medical CannabisInternational Medical sales...
Xilio Therapeutics Announces Pipeline and Business Updates and Second Quarter 2025 Financial Results
Announced updated Phase 2 data at ASCO for vilastobart, a tumor-activated, Fc-enhanced, anti-CTLA-4, demonstrating deep and durable responses and a...
Plus Therapeutics Presents Positive CNSide CSF Assay Platform Results at the 2025 SNO/ASCO CNS Metastases Conference
CNSide® can quantify leptomeningeal metastases (LM) over time and monitor changes in the expression of multiple targetable mutations CNSide® may...
New Report: Cleaner Manufacturing Could Save 77,000 Lives and Prevent Millions of Asthma Attacks
American Lung Association releases report detailing health benefits of transition to zero-emission manufacturing CHICAGO, Aug. 14, 2025 /PRNewswire/ -- Industrial...
HKBU develops Microfluidic Flow Cytomolecular Analyser to promote extensive application of precision medicine
HONG KONG, Aug. 14, 2025 /PRNewswire/ -- Testing technologies play a pivotal role in disease diagnosis. Currently, flow cytometers are widely...
Clarivate Launches AI-powered Regulatory Assistant Within Cortellis Suite to Boost Productivity and Ease Regulatory Burden
Integrated into Cortellis Regulatory Intelligence, new AI capability helps regulatory teams streamline access to critical intelligence and understand requirements with...